A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Bendamustine; Rituximab
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- 03 Mar 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2020.
- 03 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 08 Mar 2015 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov record.